Sanofi’s billion-dollar multiple sclerosis drug faces competitive threat from Novartis, J&J agents
On Friday, Novartis presented data at ECTRIMS showing that Arzerra had superior efficacy to Sanofi's Aubagio. Johnson & Johnson's Janssen division had presented data for its drug, ponesimod, two days before.